Literature DB >> 6979415

Plasma concentrations in pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting.

E Weidekamm, H Plozza-Nottebrock, I Forgo, U C Dubach.   

Abstract

For the determination of the plasma concentration profiles of pyrimethamine and sulfadoxine after the administration of 1 tablet of Fansidar, highly specific analytical methods are needed as the pyrimethamine concentration is low (0.2 - 0.02 mg/litre) and the concentration ratio of the two components in the plasma is high (> 1: 500). The microbiological method described in this paper fulfils these requirements for high specificity and sensitivity (the sensitivity limit for sulfadoxine is 1 mg/litre and for pyrimethamine is 0.013 mg/litre).Pharmacokinetic data were evaluated for 14 volunteers after administration of 1 tablet of Fansidar, and a computer simulation of multiple dosing (1 tablet per week) was performed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6979415      PMCID: PMC2536029     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  6 in total

1.  Pharmacokinetic rationale for a malarial suppressant administered once monthly.

Authors:  C C Peck; A N Lewis; B E Joyce
Journal:  Ann Trop Med Parasitol       Date:  1975-06

2.  Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man.

Authors:  J C Cavallito; C A Nichol; W D Brenckman; R L Deangelis; D R Stickney; W S Simmons; C W Sigel
Journal:  Drug Metab Dispos       Date:  1978 May-Jun       Impact factor: 3.922

3.  Chromatographic assay of mixed penicillins, ampicillin and cloxacillin in body fluids.

Authors:  T Murakawa; Y Waki; M Nishida; R Fuji; M Konno
Journal:  J Antibiot (Tokyo)       Date:  1970-05       Impact factor: 2.649

4.  Determination of plasma concentrations of dapsone, monoacetyl dapsone and pyrimethamine in human subjects dosed with maloprim.

Authors:  C R Jones; S M Ovenell
Journal:  J Chromatogr       Date:  1979-06-11

5.  Comparative toxicological, chemotherapeutic and pharmacokinetic studies with sulphormethoxine and other sulphonamides in animals and man.

Authors:  E Böhni; B Fust; J Rieder; K Schaerer; L Havas
Journal:  Chemotherapy       Date:  1969       Impact factor: 2.544

Review 6.  The treatment of malaria.

Authors:  A P Hall
Journal:  Br Med J       Date:  1976-02-07
  6 in total
  30 in total

1.  Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy.

Authors:  Sam Salman; Susan Griffin; Kay Kose; Nolene Pitus; Josephine Winmai; Brioni Moore; Peter Siba; Kenneth F Ilett; Ivo Mueller; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii.

Authors:  J M Jacobson; M Davidian; P M Rainey; R Hafner; R H Raasch; B J Luft
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  Development of recommendations for the protection of short-stay travellers to malaria endemic areas: Memorandum from two WHO Meetings.

Authors: 
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

Review 4.  Drug treatment and prevention of malaria.

Authors:  N J White
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Sulfadoxine-pyrimethamine resistant malaria from west or central Africa.

Authors:  J Gubler
Journal:  Br Med J (Clin Res Ed)       Date:  1988-02-06

6.  Scaling up of intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine: prospects and challenges.

Authors:  Wellington Aghoghovwia Oyibo; Chimere Obiora Agomo
Journal:  Matern Child Health J       Date:  2011-05

Review 7.  Clinical pharmacokinetics of antimalarial drugs.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

8.  Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis.

Authors:  Stéphane Corvaisier; Bruno Charpiat; Cyril Mounier; Martine Wallon; Gilles Leboucher; Mounzer Al Kurdi; Jean-François Chaulet; François Peyron
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen.

Authors:  Celestino Obua; Urban Hellgren; Muhammed Ntale; Lars L Gustafsson; Jasper W Ogwal-Okeng; Toufigh Gordi; Markus Jerling
Journal:  Br J Clin Pharmacol       Date:  2008-02-20       Impact factor: 4.335

10.  Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women.

Authors:  Harin A Karunajeewa; Sam Salman; Ivo Mueller; Francisca Baiwog; Servina Gomorrai; Irwin Law; Madhu Page-Sharp; Stephen Rogerson; Peter Siba; Kenneth F Ilett; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.